Biocon moves higher as its arm gets USFDA’s nod for Everolimus Tablets
Biocon is currently trading at Rs 314.95, up by 9.75 points or 3.19% from its previous closing of Rs 305.20 on the BSE.
The scrip opened at Rs 322.25 and has touched a high and low of Rs 322.25 and Rs 313.75 respectively. So far 109391 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52-week high of Rs 404.60 on 21-Jan-2025 and a 52-week low of Rs 260.00 on 19-Apr-2024.
Last one week high and low of the scrip stood at Rs 345.00 and Rs 295.30 respectively. The current market cap of the company is Rs 37884.93 crore.
The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 21.02% and 18.34% respectively.
Biocon’s wholly owned subsidiary -- Biocon Pharma has received approval for its ANDA for Everolimus Tablets from the U.S. Food and Drug Administration (USFDA), in strengths of 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg. Everolimus is a prescription medication that is indicated for the prophylaxis of organ rejection in adult patients, and in kidney and liver transplantation.
The approval will further strengthen Biocon’s portfolio of vertically integrated, complex drug products.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
